La-Radio 893

five (three votes)

Healthcare Prof:

The presence of the protein poly (ADP-ribose) polymerase (PARP) in tumours can support predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona tomorrow (Saturday 27 March). Professor Gunter von Minckwitz, from the German Breast Group Forschungs GmBH, Neu-Isenburg, says that, contrary to existing belief that PARP is related to a limited number of tumours, he and his team discovered for the initial time that PARP expression exists across all breast cancer subtypes, and that such tumours were highly sensitive to chemotherapy.

Professor von Minckwitz and his team set out to investigate the expression of PARP in several hormone receptor subtypes of early breast cancer and to evaluate regardless of whether or not it could predict a total response to chemotherapy given just before surgery. “We knew that a new class of drug known as PARP inhibitors had been useful against aggressive sorts of breast cancer like those involving BRCA mutations and triple-negative breast cancer, exactly where the tumour does not express genes for the oestrogen or progesterone receptors, or for HER2,” he says. “However, we did not fully grasp whether the presence of PARP would predict the efficacy of these drugs. Prior to exploring this, we needed to realize no matter whether PARP played any role in breast cancers, whether it was restricted to certain forms of tumours, how it correlated to existing prognostic and predictive markers, and whether or not it could predict the efficacy of chemotherapy.”

PARP is actually a protein involved in numerous cellular processes. One of its essential functions is assisting within the repair of single-strand DNA breaks. If one single-strand broken DNA is reduplicated, a double-strand broken DNA outcomes. If PARP is inhibited, cell death occurs; this implies that chemotherapy could be targeted precisely at cancer cells, whilst leaving typical, healthy cells relatively untouched. A recent conference presentation* showed that the simultaneous use of a PARP inhibitor with DNA-damaging chemotherapy in breast cancer could enhance overall survival. The prospective role of PARP inhibitors as a brand new anticancer agent is at the moment under analysis in a number of other studies.

Professor von Minckwitz’s team employed tissue from 646 patients in a neoadjuvant Phase III trial (GeparTrio) to try to find the presence of PARP and to correlate its existence with other prognostic factors and total response to chemotherapy. Neoadjuvant chemotherapy is given to patients just before other remedies including surgery or radiotherapy. They discovered that, despite the fact that PARP was present in all tumour subtypes, it occurred most often in HER2 positive and triple negative tumours, and that it correlated with most recognized prognostic variables, except HER2.

“The relationship to total response was remarkable,” says Professor von Minckwitz. “Tumours with a high degree of PARP expression had a total response in 26% of circumstances, whereas those tumours which didn’t express PARP had a total response in only 9%. Moreover, we found that the presence of PARP can provide much more accurate prognostic data than the grade of differentiation or degree of abnormality of tumours. We believe that this is the initial study to describe a broad expression of PARP in untreated breast tumours together having a correlation of sensitivity to chemotherapy.”

PARP positive tumours could become a new entity in breast cancer, the investigators say. They intend to follow up their initial findings by a trial randomising patients to either chemotherapy alone or chemotherapy plus a PARP inhibitor. “Particularly in triple-negative tumours there’s an excellent should increase treatment options,” says Professor von Minckwitz. “Apart from chemotherapy, there’s no other therapy for example endocrine or anti-HER2 therapy available for this aggressive form of breast cancer.”

However, it remains to be noticed regardless of whether immunohistochemical detection (the process of localising antigens in tissue cells) of PARP could be the ideal strategy of predicting PARP inhibitor efficacy, the scientists say. “We require a lot more prospective trials to be sure that there’s no far better way of generating confident that the correct individuals are acquiring the correct therapy,” says Professor von Minckwitz. “However, it could be fair to say that we believe that we may be on the verge of a major alter in the way breast cancer is treated.”

* O’Shaugnessy, San Antonio Breast Cancer Symposium, 2009

Abstract no: 9, Friday 15.30 hrs, Rooms 115+116

Source:
Mary Rice
ECCO-the European CanCer Organisation

four.67 (3 votes)

Healthcare Prof:

Treatment with beta-blockers can help minimize the spread of cancer in patients with breast tumours, a researcher will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona these days (Friday). In a controlled study, Dr. Des Powe, a senior healthcare investigation scientist at Queen’s Medical Centre, Nottingham University Hospital NHS Trust, Nottingham, UK, and his team identified that the group of patients treated with beta-blockers showed a significant reduction in metastasis and greater survival. The scientists think that they are the very first within the world to have investigated the effect of beta-blockers in breast cancer patients.

In collaboration with Professor Frank Entschladen’s group at Witten University, Germany, Dr. Powe looked at 3 groups of breast cancer patients: those that were already being treated for hypertension by beta-blockers, those whose hypertension was treated by other medicines, and those that did not suffer from hypertension and were for that reason not taking any treatment for it. Forty-three of the 466 patients had been already taking beta-blockers and, in this group, there were significant reductions in each distant metastasis and local recurrence. They also had a 71% reduced risk of dying from breast cancer compared using the other groups.

“We were also able to study the presence of 1prospective biomarker for predicting clinical response to beta-blocker treatment,” says Dr. Powe, “but we didn’t come across that this correlated directly towards the outcome of remedy. We’re at present searching at other target receptors as predictors of clinical outcome.”

Previous cell line laboratory studies have shown that beta-blockers work against several kinds of cancer simply because high levels of tension hormones inside the tumour boost cell proliferation and migration (the movement of cells to other places). “These effects are induced by the anxiety hormones norepinephrine and epinephrine acting on certain target receptors in a kind of lock and key fashion,” says Dr. Powe. “We sought to translate these laboratory findings into clinical research.”

Beta-blocker drugs bind to a particular type of receptor to prevent the anxiety hormones from reaching their target; in cancer cells this prevents the hormones from stimulating and activating them. The researchers say that they’re certain that their outcomes are on account of the impact of beta-blockers rather than a protective impact of hypertension per se.

“If that had been the case, we would have seen comparable survival advantages in patients receiving other types of treatment for hypertension,” says Dr. Powe, “but we did not. It really is reasonable to speculate, as a result, that some non-hypertensive ladies with breast cancer will respond favourably to beta-blocker treatment, although doses and side effects would have to be investigated in clinical trials. We also need to examine whether beta-blockers might be given as a supplementary therapy with existing breast cancer therapy.”

This finding may assist remedy in two techniques, say the researchers: it appears to slow down tumour growth and could also be employed to target those patients who’ve an increased danger of developing secondary cancers.

“Our first study is fairly modest, and we now intend to validate it in a bigger group,” says Dr. Powe. “We will probably be searching for funding and collaborators to test the effectiveness of beta-blocker therapy on patients diagnosed with breast cancer. We are really encouraged by these very first results which have already shown that by making use of a well-established, safe, and cost-effective drug, we can take an additional step on the road to targeted therapy in breast cancer.”

Abstract no: 445, Friday 15.30 hrs, Rooms 115+116

Source:
Mary Rice
ECCO-the European CanCer Organisation

five (1 votes)

Healthcare Prof:

Two studies to be presented in the seventh European Breast Cancer Conference (EBCC7) in Barcelona right now (Friday) and tomorrow (Saturday), shed light on the therapy alternatives facing women carrying the BRCA1 and BRCA2 genetic mutations which predispose them to breast cancer. In the initial, Ms Annette Heemskerk-Gerritsen, a PhD student inside the Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands, will tell the conference this afternoon (Friday) that prophylactic mastectomy (where girls who’ve been treated for breast cancer in 1 breast have the remaining breast tissue removed as a risk-reducing measure) does not boost disease-free or overall survival in this group of patients.

In the second, to be presented towards the conference tomorrow (Saturday) Professor Lori Pierce, Professor of Radiation Oncology in the University of Michigan, Ann Arbor, USA, will report the findings of an international study of treatment outcomes right after either breast conserving therapy (BCT) or mastectomy in 655 BRCA1 and BRCA2 carriers. The study discovered much more recurrences within the breast with BCT compared to recurrences in the chest wall following mastectomy, but similar rates of recurrence when BCT patients also received chemotherapy.

Women who carry a mutated BRCA1 or BRCA2 gene have a threat of between 55% and 85% of creating cancer in their lifetime, and those that do create it have to make challenging decisions about their remedy, often opting for probably the most radical therapy in the belief that they are going to have a better opportunity of overcoming their illness. Until now there has been small information on the longer-term effects of such treatments on these patients.

Ms Heemskerk-Gerritsen and her team looked at the efficacy of risk-reducing mastectomy (RRM) on disease-free and overall survival in 390 patients who carried the BRCA1/2 mutation and who had already had cancer in 1 breast. Of these, 138 patients underwent RRM, although the others continued standard surveillance. There had been no differences in age at diagnosis, hormone-receptor status, and adjuvant hormonal remedy among the RRM and non-RRM groups. The numbers of women receiving adjuvant chemotherapy as well as numbers of girls undergoing risk-reducing salpingo-oophorectomy (removal of the fallopian tubes and ovaries) were higher inside the RRM group.

During 2033 individual years observation (PYO – the total sum of the number of years that every member of the study population has been under observation), 54 patients in the non-RRM group developed metastatic illness as opposed to 18 patients in the course of 642 PYO within the RRM group, incidence rates of 0.027 and 0.028 respectively. As for overall survival, 56 girls within the non-RRM group died for the duration of 2164 PYO, and 16 inside the RRM group in the course of 682 PYO, mortality rates of 0.026 and 0.023, respectively.

“While RRM certainly reduces the incidence of breast cancer in the other breast to zero, as opposed to 66 instances within the non-RRM group, we identified that there was extremely small distinction in disease-free and overall survival between the two groups,” says Ms Heemskerk-Gerritsen. “We intend to follow up this study by identifying a set of prognostic factors associated to survival in breast cancer patients having a BRCA1 or BRCA2 mutation. In this way, we hope to be able to identify a subgroup of patients who may possibly benefit from RRM. In the meantime, we hope that our findings will provide extra info to boost the counselling of breast cancer patients considering risk-reducing mastectomy, by emphasising that the acquire that may be obtained by this radical surgery is mainly in respect of reducing the risk of contralateral breast cancer. As but we have discovered no benefits with respect to disease-free and overall survival.”

In the second study, Professor Pierce and her collaborators from the USA, Australia, Spain, and Israel found that patients treated with BCT had considerably greater rates of cancer recurring inside the breast (23.5%) than did patients who had mastectomy (five.5%) at 15 years. But when they looked at patients who had received chemotherapy too as BCT, they found that the threat of recurrence was significantly reduced and also the overall danger with this treatment was not considerably diverse from the mastectomy group (11.9%). And in spite of the higher rates of nearby recurrence inside the BCT group, other risks – metastasis, breast cancer-specific survival, and overall survival – had been comparable.

When they compared rates of developing cancer within the unaffected breast, which exceeded 40% in both groups, the researchers found that the use of radiotherapy right after surgery didn’t boost risk in comparison with those women who did not receive radiation remedy.

Although there have been several trials comparing breast conserving surgery and radiotherapy with mastectomy in girls with non-hereditary cancer, information on those ladies using the inherited type of the illness are limited and this has created it tough for patients and doctors alike to know how greatest to proceed. Ideally, the researchers say, such studies must be randomised, but due to the fact remedies for patients who carry the BRCA1/2 mutation are so individualised and also the decision-making so complex, a randomised trial is unlikely.

“To the very best of my expertise, ours will be the 1st multi-institutional systematic comparison of BCT versus mastectomy in BRCA1/2 carriers,” Professor Pierce will tell the conference. “It will supply essential information to patients trying to choose what will likely be the best remedy for their hereditary breast cancer, also as to the physicians advising them.

“If a woman with BRCA1/2-associated breast cancer is contemplating breast conserving surgery and radiotherapy, our findings show that she will have fewer recurrences in the breast if chemotherapy is also utilised. And our conclusion that 15-year outcomes of BCT and mastectomy are comparable must reassure recently diagnosed ladies who could find the believed of an immediate mastectomy overwhelming. We strongly encourage patients to talk about nearby therapy possibilities with their doctors prior to beginning treatment.”

Notes:
Abstract nos: 500, Friday 17.15 hrs, Rooms 115+116 (Heemskerk-Gerritsen), 7, Saturday 11.00 hrs, Rooms 111+112 (Pierce).
Ms Heemskerk-Gerritsen’s investigation was funded by a grant from the Dutch Pink Ribbon Foundation.
Professor Pierce’s study was funded by the Breast Cancer Research Foundation; Susan G. Komen Breast Cancer Foundation; Dana Farber/Harvard Cancer Center SPORE in Breast Cancer; Cancer Genetics Network; the Colebatch Clinical Research Fellowship of the Cancer Council Victoria, the National Wellness and Medical Research Council of Australia and grants from the National Breast Cancer Foundation, the NHMRC and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia (kconFab).

Source:
Mary Rice
ECCO-the European CanCer Organisation

5 (1 votes)

Healthcare Prof:

Trends indicate that survival is improving in patients with metastatic breast cancer, specifically in those patients whose tumours are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say nowadays (Friday 26 March) at the seventh European Breast Cancer Conference (EBCC7).

Dr Marie Sundquist, from the Department of Surgery, County Hospital, Kalmar, Sweden, will say that the median survival times for five-year intervals of 557 metastatic breast cancer patients in Kalmar, Sweden, elevated steadily, from 10 months for the 1985 to 1990 period, to 22 months for the 2000 to 2004 period.

She is going to be reporting the findings of a retrospective analysis of follow-up information of breast cancer patients who had been diagnosed in hospitals in Kalmar County considering that 1985. “A strength of our work is the fact that we have studied a consecutive population in a defined geographical region for a continuous period of 25 years,” Dr Sundquist will tell the conference.

Dr Sundquist will tell delegates that for 288 patients with grade III tumours, the most aggressive kind of breast cancer, the median survival time increased from 10 months for the 1985 to1990 period to 17 months for the 2000 to 2004 period. The elevated use of the chemotherapy drugs known as anthracyclines and taxanes led towards the improved survival outcomes in this group of patients using the aggressive form of metastatic breast cancer, she stated.

Some breast cancer cells have receptors, which permit particular kinds of hormones or proteins to attach towards the cancer cell. Breast cancer hormone-receptor status can affect the individual patient’s therapy choices at the same time as overall prognosis. Analysis of the information by HER2 positive status revealed that HER2 positive patients with metastatic breast cancer had improved survival rates. Prior towards the year 2000, 40 HER2 positive patients had a median survival of 14 months compared to 21 months for 40 HER2 positive patients diagnosed with breast cancer from the year 2000 onwards.

Dr Sundquist stated: “There is no doubt that trastuzumab (Herceptin), which targets the HER2 gene, is the most significant cause for the improved survival in this group of patients, and use of the chemotherapy drugs called anthracyclines also contributed.

“In the group of HER2 positive patients that had essentially the most aggressive form of breast cancer (grade III), 45% of those patients that received trastuzumab had survived much more than three years and 30% more than five years,” Dr Sundquist added.

“Patients whose breast tumours have spread outside of the breast and armpit areas are basically incurable. Nonetheless, some patients live even decades having a very good top quality of life despite an initially widespread tumour burden, whilst other people fail to respond to any therapy. To discover and attempt to understand these mechanisms would make it less complicated to tailor the remedy for each individual patient,” Dr Sundquist will say.

A new era of breast cancer therapy started with the gene-targeted therapy of trastuzumab. Because then, numerous comparable targeted therapies including antibodies or inhibitors of distinct genes have been developed. This will open new avenues within the treatment of all metastatic breast cancers and also of main breast cancer.

“These new targeted therapies will, a minimum of in the beginning right after their development, be very pricey for healthcare systems. On the other hand they will make it potential for a lot of girls to lead almost regular lives, perform and contribute to society for an increased number of years,” she concluded.

The researchers intend to follow up their work by performing genetic analyses of the tumours with different responsiveness to specific remedies. “Health care systems will need to present tools for the routine clinical assessment of quite a few genes related to treatment response,” she added.

Abstract no: 453

Source:
Kay Roche
ECCO-the European CanCer Organisation

View drug details on Herceptin.

5 (1 votes)

Healthcare Prof:

Women who’re diagnosed with breast cancer inside the 12 months following they have completed a pregnancy are 48% more most likely to die than other young ladies with breast cancer based on new study to be presented in the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday).

However, the study of two,752 breast cancer patients by Australian researchers discovered that if the breast cancer was diagnosed while the girls had been pregnant, their danger of dying was almost exactly the same as other, non-pregnant ladies diagnosed with breast cancer – only 3 percent greater.

Assistant Professor Angela Ives, a research fellow in the University of Western Australia, will tell the conference that the findings suggest that the cumulative effect of pregnancy may play a role in breast cancer prognosis and this, together with whether or not a woman breast feeds, needs further investigation.

However, she stated: “It is important to stress that our findings shouldn’t discourage girls from breast feeding as we know that this is useful to each mother and baby in quite a few methods. Although most breast symptoms or abnormalities identified in young girls are benign, it is essential that when a woman is pregnant or breast feeding any symptoms or abnormalities are not assumed to be due to the pregnancy or breast feeding, especially if the symptoms persist. It truly is important that both health professionals and young ladies are breast aware, even throughout pregnancy and breast-feeding, and promptly have symptoms investigated to allow early diagnosis.

“For girls who’re diagnosed with breast cancer soon after pregnancy, they and their clinicians could wish to consider different forms of remedy to improve survival.”

Prof Ives stated that due to the fact really little is recognized about gestational breast cancer (breast cancer which is diagnosed even though a woman is pregnant or as much as 12 months following completion of a pregnancy, such as terminations or miscarriages) she and her colleagues decided to come across out a lot more to ensure that ladies could make informed choices about their breast cancer management and pregnancy outcome.

Using the Western Australia Information Linkage Program, they identified a group of 2,752 ladies, aged much less than 45, diagnosed with breast cancer in Western Australia among January 1982 and December 2003. They followed them to December 2007 or to their date of death, if earlier.

“The WA Information Linkage Method is 1 of only 5 comprehensive record linkage systems within the world. It brings together population-based hospital morbidity information, birth and death records, mental health services data, cancer registrations and midwives’ notifications, linked back to 1980. In this case we have been able to identify all situations of gestational breast cancer diagnosed in WA and all other instances of breast cancer in similar aged women to identify what is different about them,” she stated.

The researchers took account of further elements such as age at diagnosis, histological tumour grade, stage of disease and no matter whether the cancer had spread towards the lymph nodes. From the total number of females, 182 had been diagnosed with gestational breast cancer, 55 while they were pregnant and 127 soon after the finish of the pregnancy. Prof Ives located that, as could be expected, histological tumour grade, illness stage and lymph node involvement had been all associated with a worse survival for all the girls. The finding of the increased danger of death if breast cancer was diagnosed soon after pregnancy remained after adjusting for lymph node status, disease stage at diagnosis, histological tumour grade and age.

Prof Ives said: “It has been assumed over a lot of years that actually being pregnant at diagnosis led to poor survival, but this study has shown that it might be the quantity of time that a woman is pregnant and her body’s responses to becoming pregnant that encourage the growth of a breast cancer. Yet another explanation might be that the changes inside the breast whilst pregnant after which breast feeding mask a breast cancer, which is, consequently, far more advanced when it is diagnosed. It might be a mixture of each. Additionally, we do know that pregnancy and breast-feeding reduce the long-term threat of a woman developing breast cancer, but we also know that, within the short term, having been pregnant might increase the risk of developing breast cancer. There wants to be further study into these possible explanations for our findings.”

Prof Ives and her colleagues are now investigating what may be happening at cell level with the way tumours grow (angiogenesis) as well as the role played by the body’s immune response. They are also carrying out further research on the cumulative impact of pregnancy and breast-feeding and time from conception to date of cancer diagnosis on survival.

In a second study, Dr Salma Butt (M.D. plus a PhD student at the Department of Surgery, Malm? University Hospital, Sweden) examined the link between the length of time that females breast-fed as well as the diverse sorts of breast cancer they subsequently developed. She found that even though the risk of developing breast cancer was the same regardless of the duration of breast-feeding, women who had breast-fed for six months or longer had a statistically significant risk of developing a lot more aggressive sorts of breast cancer. Nonetheless, Dr Butt and her colleagues do not know yet whether or not this indicates that these females are more likely to die from their cancer.

Dr Butt said: “Several previous studies have investigated the association in between breast-feeding and breast cancer risk, but, to our understanding, no studies have investigated breast-feeding and danger associated with diverse types of breast cancer. Furthermore, no study has investigated the association among breastfeeding, sorts of breast cancer and survival yet.

“Our findings need to have be followed by studies on survival to see if these more aggressive breast tumours in fact lead to a higher death rate or not, due to the fact we do know that breast cancers that don’t have aggressive characteristics may also have high rates of mortality if they’re diagnosed late. This is something that we intend to study subsequent.”

Dr Butt and her colleagues examined information collected prospectively from a group of 17,035 girls inside the Malm? Diet program and Cancer Study. They evaluated 622 instances of breast cancer for a range of aspects that indicated how aggressive the tumours had been (e.g. invasiveness, tumour size, axillary lymph node status, HER2 status, Ki67, which is an indicator for tumour proliferation, etc). They analysed the duration of breast feeding for each child, total quantity of time a woman had breast-fed, as well as the typical time of breast-feeding per child; the average duration of breast feeding was divided into 4 groups: less than two.2 months, less than 4 months, 4 months or far more, and 6.2 months or far more.

Dr Butt stated: “We discovered a statistically substantial threat of grade III tumours in females with an typical time of breast-feeding of 6.two months or much more. The risk of tumours expressing higher levels of Ki67 was also considerably associated with longer duration of breast-feeding. We concluded that long duration of breast-feeding was associated with more unfavourable forms of breast cancer.”

She stressed that these findings shouldn’t discourage women from breast-feeding as there were several powerful studies that showed that breast-feeding could decrease a woman’s overall threat of breast cancer, and that longer breast-feeding occasions were excellent for each mother and baby.

“The most important thing would be to identify females having a higher danger of aggressive types of breast cancer and provide them intensified screening, as a way to identify their tumours early.”

She said the study was an epidemiological one that could show danger associations but not causes. “The biological mechanisms behind this are still to be identified. What’s recognized is that breast-feeding reduces the number of ovulatory menstrual cycles more than a lifetime, thereby decreasing the impact of hormone levels present throughout typical menstrual cycles and, in particular, decreasing the progesterone exposure. This may explain the discovering in previous studies of a decreased threat of breast cancer in girls who had breast-fed. Nonetheless, breast-feeding stimulates the production of prolactin, a hormone that has been reported to have tumour-promoting effects. But the relation between breastfeeding, prolactin and breast cancer is complicated and not completely understood.”

Source:
Emma Mason
ECCO-the European CanCer Organisation

five (1 votes)

Healthcare Prof:

5 (1 votes)

Women who discover they’ve breast cancer even though they’re pregnant might be treated with chemotherapy without endangering the health of their unborn baby, according to investigation to be presented in the seventh European Breast Cancer Conference (EBCC7) in Barcelona these days (Friday).

Dr Sibylle Loibl, Assistant Professor in Obstetrics and Gynaecology at the University of Frankfurt, Germany, as well as a member of the German Breast Group, will tell the conference that pregnant breast cancer patients might be treated as close as feasible to normal recommendations because chemotherapy delivered even though babies had been within the womb did not appear to trigger the babies significant issues at or after birth.

“Until now, the evidence upon which we based our decisions about how to treat pregnant females with breast cancer has been largely limited to case studies and retrospective investigations. For this reason doctors have tended to be cautious in their approach to treatment because of fears concerning the impact it may have on the foetus, although it meant that girls did not necessarily receive the best remedy for their cancer,” stated Dr Loibl. “Therefore, the German Breast Group set up a registry to collect information both retrospectively and prospectively from patients who’ve been diagnosed with breast cancer throughout pregnancy. It’s the only international registry to focus on the outcomes of each the mother along with the baby.”

The researchers entered particulars of 235 patients prospectively (119) and retrospectively (116) to the registry in between April 2003 and October 2009. The ages of the females ranged in between 23 and 46 with an typical (median) age of 33. Breast cancer was diagnosed, on typical, at 23 weeks into the pregnancy. Not all the information are total yet, but out of 151 girls, 91 received an average of two cycles of chemotherapy whilst they were pregnant.

The typical gestational age of the babies at the time of delivery was 36 weeks, ranging among 28 and 42 weeks. Babies that had been exposed to chemotherapy throughout pregnancy had been born slightly lighter than babies who were not: an typical of 2636mg, compared to 2791mg.

Of the 91 babies exposed to chemotherapy, three had been born bald (alopecia), one was small for gestational age, one had trisomia 18 (a chromosomal disorder) and died one week following birth, 1 had necrotic enterocolitis (a severe bacterial infection of the intestine) and died 3 weeks soon after birth, 1 developed sepsis (blood infection), 1 developed neutropenia (low white blood cell count) and two had anaemia. Of the 60 babies who had been not exposed to chemotherapy, 1 had temporary apnoea (breathing interruption), 1 had an increase in C reactive protein (a protein that appears in response to inflammation or infection) and 1 had gastroenteritis.

Dr Loibl stated: “Most of the problems described in the babies exposed to chemotherapy were not related to the therapy but were most possibly because of other circumstances (for example, necrotic enterocolitis as a result of preterm delivery or trisomia 18). Usually, in nature, there is a threat of malformations of in between 1 and two percent, and other difficulties such as infection can take place. The foetal outcomes of these babies that received chemotherapy had been not substantially various from those who didn’t.

“Therefore, this study suggests that pregnant breast cancer patients might be treated as close as feasible to normal recommendations and obtain chemotherapy, if it’s indicated, even though they’re pregnant. Ideally, this ought to take location within the care of specialised, multidisciplinary teams. We would like to produce more robust data to confirm this and so the registry is continuing and we are updating and completing the information.”

In addition towards the information on outcomes for mothers and babies, Dr Loibl and her colleagues are also collecting tumour specimens and placenta material from the females who’re being followed prospectively, and these are sent to the German Breast Group’s biomaterial bank. The researchers hope that this can give them important information in the future about the effects of pregnancy and chemotherapy on outcomes for mothers and babies.

Source:
Emma Mason
ECCO-the European CanCer Organisation

Healthcare Prof:

Women who’ve been treated for breast cancer can choose to turn into pregnant and have babies, without fears that pregnancy could put them at greater danger of dying from their cancer, according to a significant, new study.

In a meta-analysis of 14 trials, presented (Friday) in the seventh European Breast Cancer Conference (EBCC7), researchers from Belgium and Italy found that, not simply was pregnancy safe for breast cancer survivors, but, the truth is, it could boost their probabilities of survival.

Breast cancer is the most typical cancer for women in the course of their childbearing years. As females delay starting a family until they are older, along with the survival from breast cancer has improved, growing numbers of breast cancer survivors need to have babies after their cancer therapy has finished. Till now, it was unclear whether or not it was secure for them to do so, due to concerns that the hormonal alterations related to pregnancy, in specific the boost in oestrogen, could prompt the cancer to recur or grow to be more aggressive.

Dr Hatem A. Azim, Jr., a Fellow at the Department of Medical Oncology in the Institute Jules Bordet (Brussels, Belgium), and colleagues in Italy analysed outcomes from 14 trials that had taken location among 1970 and 2009, involving 1,417 pregnant ladies having a history of breast cancer and 18,059 women with a history of breast cancer who had been not pregnant.

They identified that patients who became pregnant following a diagnosis of breast cancer had a significant reduction of 42% within the threat of death compared to breast cancer survivors who did not get pregnant.

Dr Azim stated: “Our findings clearly demonstrate that pregnancy is secure in females with history of successfully treated breast cancer. There is a wide perception in the oncology community that women with history of breast cancer should not get pregnant for fear of pregnancy growing the danger of recurrence by means of hormonal stimulation. This meta-analysis strongly argues against this notion.

“Now we’re refining the outcomes by analysing subgroups to examine the impact of the timing of pregnancy for instance how soon right after a breast cancer diagnosis is it secure to grow to be pregnant and differences in survival based on the patient’s age, lymph node status and so on.

“It is nonetheless typical that patients are faced with incorrect counselling regarding pregnancy as well as the chances of future fertility following the end of breast cancer remedy and, therefore, they’re denied the chance of obtaining pregnant. Nowadays, there is a rising trend of delaying pregnancy to later in life and far more young girls are cured from breast cancer. So it’s important to present high degree of evidence to help physicians in counselling these patients. This work may possibly lead to improving the good quality of life of millions of young girls who finish their adjuvant breast cancer therapy and need to get pregnant.”

Dr Azim stated there may be numerous explanations related to hormones or the immune method as to why pregnancy seemed to confer a protective impact on breast cancer survivors.

“It is well-known that oestrogen is related to breast cancer development. Nonetheless, beyond a particular level, oestrogen exerts inhibitory effects on breast cancer cells. Laboratory experiments have shown that oestrogen and progesterone receptors situated on 60-70% of breast tumours undergo apoptosis (programmed cell death) when exposed to high levels of oestrogen, which possibly mimics levels encountered in the course of pregnancy. In addition, prolactin is elevated in pregnancy and there is evidence suggesting that ladies with high levels of prolactin have a reduced threat of breast cancer relapse.” He added: “Nevertheless, hormonal changes in the course of pregnancy are really complicated, and the effect observed in this study could possibly be the result of the interaction of the distinct hormones as opposed to an action of a particular one by itself.

“Immunological theories could partially clarify the potential protective value of pregnancy as well. It has been shown that foetal antigens* are expressed on the tumour cells of the mother. Therefore, antibodies produced by the mother in response to these antigens, might act as a type of tumour vaccination.”

Dr Azim said that they had contacted all the authors of trials published following 1995 to get additional info on subgroups, and this would inform their further analysis.

He concluded: “Nowadays, fertility soon after cancer has become a best issue not just for patients, but also physicians. In 2006, the American Society of Clinical Oncology published guidelines that state that fertility concerns should be discussed with patients just before therapy a recommendation we think is of wonderful importance.”

Source: The European Cancer Organisation (ECCO)

3.33 (three votes)

Healthcare Prof:

Women who’ve been diagnosed with breast cancer think the threat of the illness occurring in their unaffected breast is as considerably as ten times higher than it really is. Consequently, they are choosing to have prophylactic mastectomies based on a false perception of increased risk, according to new study.

However, Mr Ajay Sahu MD, a consultant breast surgeon in the Frenchay Hospital (Bristol, UK), will tell the seventh European Breast Cancer Conference (EBCC7) (Thursday) that if the girls are given time to think and counselling to help them understand their actual danger, they usually make a decision against a prophylactic mastectomy. The results of his research could lead to a reduction inside the numbers of prophylactic mastectomies, at the same time as saving women from unnecessary side-effects caused by the therapy.

Mr Sahu reached his conclusions after conducting a study of 27 consecutive patients, aged among 31-65, who were diagnosed with breast cancer between April 2007 and October 2009, and who had been having surgery on one breast but were requesting that the other breast should be removed too.

“I set out to do this study simply because the incidence of contralateral prophylactic mastectomy was growing in my unit,” he said. “I felt that the time of diagnosis was a moment of increased pressure and not the best time to create such a selection. You will find two aspects to this study. One is the patients’ perception of danger in the time of diagnosis along with the other is whether or not this perception may be influenced by deferring the decision-making process.”

There is no evidence that girls who have a single, tiny breast tumour or who’re at low to moderate danger of creating a further breast cancer, acquire any survival benefit from a mastectomy or perhaps a contralateral prophylactic mastectomy (removal of the other, unaffected breast). “Yet these procedures are increasingly being accepted as patient selection and supplied by clinicians who don’t address the possibility of an inaccurate perception of risk as the reason behind their patient’s request,” said Mr Sahu. “The incidence of contralateral prophylactic mastectomy has almost doubled in recent occasions with out any evidence of survival benefit along with the causes for this need to be addressed and alternative methods considered.”

The reasons given by the 27 Frenchay patients for requesting a contralateral prophylactic mastectomy included: young age, but without having a family history (3 patients), lobular cancers (seven patients), family members history, which was deemed low risk by the surgeon (12 patients), poor knowledge of therapy outcome among household or buddies (four patients), plus a desire to stay away from radiotherapy (1 patient). All of the patients thought that they wouldn’t live longer than five years, and all overestimated their danger of contralateral breast cancer by a factor of 5 to ten.

Mr Sahu asked about the patients’ perception of danger along with the cause behind a request for prophylactic mastectomy at the time of diagnosis and then the operation was deferred. Breast care nurses counselled the patients in the time of diagnosis and when the post-operative outcomes and plans for adjuvant remedy had been discussed. The patients received adjuvant chemotherapy and/or radiotherapy and were followed up at six months by the breast care nurses and at 12 months by the surgeon. At the end of twelve months those who nonetheless requested prophylactic surgery were provided the operation.

However, in the end of the 12 months all the patients had been much less anxious about their threat. 4 patients (3 having a loved ones history and one with lobular cancer) were happy with the actual risk but nonetheless asked for prophylactic surgery. The remaining 23 patients were pleased to have had the opportunity to rethink and chose not to have prophylactic surgery.

Mr Sahu said that the 12 months delay prior to any prophylactic surgery didn’t make the women more anxious. “The ‘cooling off period’ actually helped to decrease anxiety (even though we did not discover this particularly) and helped the females to be comfortable using the choice they produced in the finish. Patients had been happy with the alternative technique to prophylactic surgery: in other words, they had an understanding of actual danger of bilateral breast cancer, an understanding that the threat could be reduced by therapy and surveillance by annual mammography, and that no survival benefit is conferred by the operation.

“Although this study is modest and should be treated with caution at this early stage, the critical message is the fact that the patient’s selection could be according to inaccurate overestimation of threat at the time of diagnosis, and, given time, they might not have the same danger perception later on. Healthcare professionals really should be conscious of this and offer you a ‘cooling off’ period to facilitate proper decision-making. The study is continuing and when we have recruited more patients we hope to be able to make much more definite recommendations.”

Mr Sahu is continuing his investigation by studying the psychological aspects of patients’ decision-making processes.

Source: The European Cancer Organisation (ECCO)

three.75 (4 votes)

Healthcare Prof:

1.67 (three votes)

The London Breast Clinic right now announced that it’s to be the initial breast clinic in Europe to offer their patients BCtect?, a blood based test for early detection of breast cancer.

“We are pleased with this development to optimise the choices and care obtainable for girls with complicated breast screening needs”, stated Fiona MacNeill, Surgical Director of The London Breast Clinic, 108 Harley Street, London.

“I think that this test will be the most significant development inside the detection of early breast cancer in the last decade worldwide”, stated Dr James MacKay, Genetic Oncologist in the London Breast Clinic. “Regular mammographic screening still misses cancers. To be able to provide such a test as BCtect? alongside standard mammography is an exciting prospect for us. Growing the pick up rate of early breast cancer in young girls is especially critical. I will consult with patients right after their mammogram and prior to the blood being taken at Quest Diagnostics, 10 Upper Wimpole Street and then again using the results. Information from The London Breast Clinic and also in other studies has shown that in recent years about 40% of cancers diagnosed from symptomatic referrals have been in patients below the age of the National Breast Screening Programme ”

BCtect?,uses blood as the sample material and detects cancer at an early stage. Early detection is the crucial to survival in breast cancer and current diagnostic methods have limitations in their diagnostic accuracy in females with dense breasts. BCtect? has the potential to distinguish in between benign and malignant illness. BCtect? is as accurate in premenopausal as in postmenopausal females, and across cancer stages and sorts. These unique characteristics offer improved early diagnostic capabilities in premenopausal females over present technologies. With its rapid and convenient sample collection BCtect? enables improved breast cancer diagnosis.

Source
The London Breast Clinic

3 (1 votes)

Healthcare Prof:

Article Opinions:1 posts
Recently published research has shown that some breast cancer patients taking tamoxifen may not be getting the full benefit of their therapy because they’ve also been taking selective serotonin reuptake inhibitors (SSRIs), prescribed drugs that inhibit the effect of an critical enzyme. Now researchers have developed a strategy for overcoming this problem, the seventh European Breast Cancer Conference (EBCC7) in Barcelona heard. Mr. Sean Hopkins, a clinical pharmacy specialist in breast cancer in the Ottawa Hospital Regional Cancer Centre, Ottawa, Canada, presented his research which shows that changing drug therapy at an early stage can aid patients get the full benefit of tamoxifen and aid the effectiveness of their remedy.

Tamoxifen is used both to prevent development of oestrogen-receptor-positive cancer and as a therapy to stop it coming back. Taking medications for example fluoxetine (Prozac) and paroxetine for depression (and in some patients hot flashes), and bupropion (Zyban) for smoking cessation, can inhibit the action of CYP2D6, an enzyme that’s related to drug metabolism and response to remedy, and which is crucial towards the metabolism of tamoxifen for breast cancer.

Mr. Hopkins and his team set out to investigate how a lot of patients taking hormonal therapy for breast cancer were also becoming prescribed CYP2D6 inhibitors. Investigation has shown that as much as 25% of breast cancer patients have depressive disorders, and numerous of them are prescribed SSRIs. Furthermore, several patients with cancer try to give up smoking and may use non-nicotine replacement therapies, such as buproprion.

“The study published recently by the Toronto group1 looked at how outcomes had been associated to remedies that the patients were taking concurrently,” says Mr. Hopkins. “Our study differs in that we have been able to take action as soon as we have discovered that a patient is taking interacting medication(s) by contacting the prescribing doctor in order to get them to switch to a different medication with no deleterious impact on tamoxifen metabolism.”

In numerous cases, Mr. Hopkins was in a position to identify those patients utilizing interacting SSRIs before starting tamoxifen remedy, either to give them time to be weaned off onto an additional class of drug or to start them on a various cancer therapy for example an aromatase inhibitor (AI). CYP2D6 inhibitors do not have exactly the same impact on AIs, but one in 5 patients discontinue taking AIs because of side effects2; if they change to tamoxifen even though continuing to take enzyme inhibitors, there may possibly be a longer overlap of therapies, says Mr. Hopkins.

“For these patients, getting the information to be able to plan effectively in advance is important, as it can take several weeks to wean patients off CYP2D6 inhibitors, and this could impact their breast cancer therapy. The findings mean that great communication between all healthcare providers is more essential than ever in order to eliminate the risk of decreasing the efficacy of prescribed therapy,” he will say.

Using drug information from his hospital’s Breast Cancer Illness Site Group clinical database, the researchers logged any patient on tamoxifen or AI therapy also as those on CYP2D6 inhibitors. A total of 531 patients were found to be eligible for the study; 463 received 1 of the prescribed hormonal therapies, while 68 were on a CYP2D6 inhibitor but not receiving hormonal treatment. Seven patients receiving tamoxifen and 16 taking an AI had been also on a strong CYP2D6 inhibitor – 5 percent of all of the patients studied. 1 patient on tamoxifen and six on an AI were also receiving a moderate enzyme inhibitor, and 24 on tamoxifen and 40 on an AI were taking weak CYP2D6 inhibitors.

Tamoxifen must be metabolised in the liver just before it can grow to be active. “We have known for a whilst that patients with a deficiency in CYP2D6 activity didn’t derive the full benefit from tamoxifen because they cannot metabolise it to endoxifen, its active metabolite,” says Mr. Hopkins. “CYP2D6 medications can mimic this pharmacogenomic phenotype by inhibiting the metabolism of tamoxifen and hence lowering its therapeutic impact.”

The team now intends to follow up the perform by expanding top quality assurance on therapies to every breast cancer patient currently under remedy in the centre – more than 6000 a year – and by exploring CYP2D6 testing for some of those patients. Such tests just before treatment begins can support physicians identify those patients having a CYP2D6 deficiency and permit the possibility of offering AI as opposed to tamoxifen therapy from the outset.

“The perform we have done demonstrates why excellent communication and seamless data transfer is so crucial in wellness care,” says Mr. Hopkins. “Patients can get care from several distinct well being care professionals – oncologists, other specialists, loved ones doctors etc – and they can get medications from numerous pharmacies. If there’s insufficient info transfer between the individuals who care for a patient, the risks of drug interactions increase, and this can impact the quality and efficacy of care becoming given.

“I believe that we should have policies in location to require well being care providers and their agencies, such as private insurance companies, to present far better access to details for wellness care specialists involved in patient care. If these organisations make an effort to protect their info in an unreasonable manner it can seriously impact care and outcomes for patients.”

1 C. M. Kelly et al, BMJ 2010;340:c693
2 S.F. Dent et al, Breast Cancer Res Treat 106 (Suppl. 1) (2007), p. S111 Abstract no: 13, Poster Discussion

Source:
Mary Rice
ECCO-the European CanCer Organisation

View drug details on Prozac Weekly; Zyban Sustained-Release Tablets.